Annovis Bio, Inc. (ANVS)

USD 4.71

(-7.83%)

EBITDA Summary of Annovis Bio, Inc.

Annovis Bio, Inc.'s latest annual EBITDA in 2023 was -45.03 Million USD , down -76.53% from previous year.
Annovis Bio, Inc.'s latest quarterly EBITDA in 2024 Q1 was -7.8 Million USD , up 25.21% from previous quarter.
Annovis Bio, Inc. reported an annual EBITDA of - USD in 2022, down -75.93% from previous year.
Annovis Bio, Inc. reported an annual EBITDA of - USD in 2021, down -165.76% from previous year.
Annovis Bio, Inc. reported a quarterly EBITDA of -7.8 Million USD for 2024 Q1, up 25.21% from previous quarter.
Annovis Bio, Inc. reported a quarterly EBITDA of -9.75 Million USD for 2023 Q2, up 2.11% from previous quarter.

Annual EBITDA Chart of Annovis Bio, Inc. (2023 - 2017)

Historical Annual EBITDA of Annovis Bio, Inc. (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	-45.03 Million USD	-76.53%
2022	- USD	-75.93%
2021	- USD	-165.76%
2020	- USD	-589.75%
2019	- USD	-10.8%
2018	66.00 USD	-4.62%
2017	84.00 USD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-7.76 Million USD	0.6%
2024 Q1	-7.8 Million USD	25.21%
2023 Q2	-9.75 Million USD	2.11%
2023 Q3	-14.71 Million USD	-50.79%
2023 FY	- USD	-76.53%
2023 Q1	-9.96 Million USD	-214.61%
2023 Q4	-10.44 Million USD	29.04%
2022 Q3	-7.67 Million USD	12.33%
2022 Q2	-8.75 Million USD	-48.03%
2022 Q1	-5.91 Million USD	0.11%
2022 FY	- USD	-75.93%
2022 Q4	-3.16 Million USD	58.71%
2021 FY	- USD	-165.76%
2021 Q4	-5.92 Million USD	-107.45%
2021 Q3	-2.85 Million USD	-12.94%
2021 Q2	-2.52 Million USD	21.04%
2021 Q1	-3.19 Million USD	-87.69%
2020 Q4	-1.7 Million USD	-67.66%
2020 Q3	-1.01 Million USD	56.46%
2020 Q2	-2.33 Million USD	-484.98%
2020 FY	- USD	-589.75%
2020 Q1	-399.22 Thousand USD	-608.01%
2019 Q1	-186.79 Thousand USD	-11.15%
2019 Q4	-56.38 Thousand USD	76.68%
2019 Q3	-241.79 Thousand USD	13.51%
2019 FY	- USD	-10.8%
2019 Q2	-279.57 Thousand USD	-49.67%
2018 Q4	-168.05 Thousand USD	-22.0%
2018 FY	- USD	-4.62%
2018 Q3	-137.74 Thousand USD	36.86%
2018 Q2	-218.16 Thousand USD	-14.85%
2018 Q1	-189.96 Thousand USD	0.0%
2017 FY	- USD	0.0%

Peer EBITDA Comparison of Annovis Bio, Inc.

Name	EBITDA	EBITDA Difference
ADC Therapeutics SA	-146.76 Million USD	69.314%
Alto Neuroscience, Inc.	-34.56 Million USD	-30.302%
Biohaven Pharmaceutical Holding Company Ltd.	-429.13 Million USD	89.506%
Ginkgo Bioworks Holdings, Inc.	-821.29 Million USD	94.517%
Nuvation Bio Inc.	-99.6 Million USD	54.784%
Nuvation Bio Inc.	-99.6 Million USD	54.784%
Arcus Biosciences, Inc.	-283 Million USD	84.087%
Theriva Biologics, Inc.	-19.85 Million USD	-126.831%
Zymeworks Inc.	-129.95 Million USD	65.346%